<?xml version="1.0" encoding="UTF-8"?>
<p>Ninjin'yoeito was administered to patients with IPF in this study. The treatment improved subjective symptoms such as, loss of appetite, malaise, and breathlessness, as well as scores related to nutritional status, including body weight and blood albumin and Hb levels. In a basic pharmacological study using a bleomycin-induced pulmonary fibrosis model, ninjin'yoeito was reported to have suppressed decreases in food intake and body weight, atrophy of the gastrocnemius, and expression of inflammatory cytokines in the lungs (
 <xref rid="B8" ref-type="bibr">8</xref>). Regarding the mechanism by which it improves loss of appetite, activation of ghrelin-responsive, and unresponsive neuropeptide Y neurons in the arcuate nucleus of the hypothalamus (
 <xref rid="B9" ref-type="bibr">9</xref>) and actions mediated by dopamine D
 <sub>2</sub> receptors (
 <xref rid="B10" ref-type="bibr">10</xref>) have been reported.
</p>
